GlobeNewswire by notified

iSTAR Medical conducts first MINIject® surgeries in Ireland, expanding commercial rollout in Europe

Share

For immediate release

iSTAR Medical conducts first MINIject® surgeries in Ireland, expanding commercial rollout in Europe

WAVRE, Belgium — 31 October 2023: iSTAR Medical, a medtech company delivering breakthrough eye care solutions to patients, today announces that the first patients in Ireland have been implanted with MINIject®, expanding the commercial rollout of the Company’s minimally-invasive glaucoma surgery (MIGS) device across Europe.

Glaucoma is the leading cause of blindness in Ireland, with the incidence of the condition expected to rise by 33% over the coming decade1. Patients in Ireland with open-angle glaucoma will now have available to them, a powerful new treatment option and will be able to benefit from the many advantages offered by MINIject® compared to traditional treatment methods. Currently the only commercially available supraciliary MIGS implant, MINIject® has demonstrated meaningful and sustained performance, combined with a favorable safety profile.

Patients were successfully implanted with MINIject® at the IOES (Institute of Eye Surgery), Mullingar, by Mr. Anish Dhital. This follows iSTAR Medical’s recent expansion of MINIject® into other European countries including Sweden and Norway.

Mr. Anish Dhital,Cataract and Glaucoma Specialist at the IOES (Mullingar) said: “The successful implantation of iSTAR Medical’s MIGS device MINIject® marks another milestone in the advancement of glaucoma treatment in Ireland. Our ability to offer a new glaucoma implant that can significantly and safely lower IOP, and target a new drainage pathway will benefit patients – enabling them to reduce reliance on medication and preserve their vision for longer.

Michel Vanbrabant, CEO of iSTAR Medical, commented:“It is both exciting and validating that one of Ireland’s largest network of eye clinics to offer all ocular sub-specialties, the IOES, has engaged with our technology and we want to thank the clinicians for their commitment. The continuation of our commercial rollout of MINIject®with the recent implantations in Ireland represents iSTAR Medical’s mission to preserve the vision of glaucoma patients around the world. We are proud to be providing more patients with a safe and minimally-invasive treatment for open-angle glaucoma, giving them a sustained and prolonged treatment option. As we continue with our global expansion, we look forward to makingMINIject® more widely available to patients.”

– Ends –

For more information

Paul van Hagen
Chief Financial Officer, iSTAR Medical
news@istar-medical.com

For media
ICR Consilium
Amber Fennell, Chris Welsh, Kris Lam
iSTAR@consilium-comms.com

About iSTAR Medical
iSTAR Medical is committed to delivering breakthrough eye care solutions. Our most advanced product, MINIject®, is approved in Europe for the treatment of open-angle glaucoma – the leading cause of irreversible blindness – and we are aiming to seek market approval in the US. We believe MINIject®’s distinctive tissue-integrating capabilities unlock a safer, and more effective option for patients. We are building an exceptional team and pipeline of potentially leading products such as MINIject® to establish new treatment paradigms in eye care conditions with the highest patient needs.

iSTAR Medical is an independent company which entered a strategic partnership with AbbVie (NYSE: ABBV) in July 2022. The collaboration further supports the role of MINIject® in the treatment of glaucoma and accelerates iSTAR Medical’s goal to bring MINIject® to more patients globally while providing AbbVie the opportunity to further expand its diverse eye care portfolio.

About MINIject®
MINIject® is iSTAR Medical’s innovative MIGS device for patients with primary open-angle glaucoma. MINIject® combines the distinctive porous structure of its proprietary STAR material with the power offered by the supraciliary space. As a result, it is designed to enhance natural fluid outflow, reducing intraocular pressure (IOP) and the need for medication, while bio-integrating with surrounding tissue, limiting inflammation, fibrosis and subsequent complications.

About Glaucoma
Glaucoma is a progressive disease affecting over 100 million people globally, of which primary open-angle glaucoma is the most common form.2,3 IOP reduction, through medication or surgery, helps delay disease progression.4 Medication is generally the first line treatment, but the progressive addition of multiple drops can burden patients with side effects, compliance challenges and costs.3,4 Invasive surgery can present risks with irreversible complications and often requires long-term patient management.3,4 MIGS is the most promising and fastest-growing glaucoma therapy due to its enhanced safety profile.3 MINIject® is potentially best-in-class for its promising long-term efficacy and safety.

https://upmc.ie/blog/what-is-glaucoma
2 Jonas JB, Aung T, Bourne RR et al. "Glaucoma". Lancet 2017; 390: 2083–93
3 Market Scope, “2021 Glaucoma Surgical Device Market Report”, July 2021.
4 “European Glaucoma Society Terminology and Guidelines for Glaucoma”, 4th Edition: British Journal of Ophthalmology. 2017;101:1-195 https://bjo.bmj.com/content/101/5/73

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Storaktionærmeddelelse29.2.2024 14:12:50 CET | pressemeddelelse

Selskabsmeddelelse nr. 6-2023/24 29. februar 2024 Storaktionærmeddelelse InterMail A/S oplyser i medfør af § 30 i lov om kapitalmarkeder, at Expon ApS i dag har meddelt at have erhvervet 180.382 aktier i InterMail, således at Expon ApS ejer mere end 5% af aktiekapitalen i InterMail. Venlig hilsen InterMail A/S Yderligere oplysninger: John Dueholm, Bestyrelsesformand Telefon: 31 24 49 31 E-mail: rdujdu@gmail.com InterMail er et datadrevet kommunikationshus, som rådgiver kunder i at skabe leads, salg samt øge kundeloyaliteten. Vi arbejder sammen med mere end 500 virksomheder, og hjælper dem med at skabe tydelige forretningsmæssige resultater på platforme som Google, Facebook, LinkedIn, Instagram samt via direct mails. Det kan vi fordi vi har erfarne og dygtige specialister med stor faglig ekspertise og mange års forretningsmæssig erfaring. Vedhæftet fil Selskabsmeddelelse 6 2023-24 - Storaktionærmeddelelse

Another milestone reached: Authorities advertise licence to be issued of 10,000-tonnes of salmon in Ísafjarðardjúp29.2.2024 14:04:53 CET | Press release

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Bíldudalur, 29th of February 2024 Arnarlax, a company wholly owned by Icelandic Salmon, has been informed that the Icelandic Food and Veterinary Authority (MAST) and Environment Agency of Iceland (UST) have advertised a licence to be issued to Arnarlax of a salmon farming license in Ísafjarðardjúp. The license will be for 10,000 tonnes maximum allowed biomass of sterile salmon. “This announcement marks another a significant milestone for us. It has been a long process, and we are glad to see our application now moving forward towards the finishing line. We are excited about the future and ready to utilize this opportunity for further sustainable growth,” says CEO Bjørn Hembre. The license is under consultation until 2.4.2024 on MAST and UST’s homepages: https://www.mast.is/ and https://ust.is/. During the consultation period, comments and feedback is invited, and may

Momcozy Earns Top Product Awards in 2024 Maternity and Baby Care Contests29.2.2024 14:01:15 CET | Press release

LONDON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Momcozy, a world-renowned maternity and baby care brand, has recently garnered a number of prestigious awards, marking a successful start to 2024 and reinforcing its global leadership in motherhood empowerment. Momcozy earned a pair of Gold Awards from Bizziebaby, a United Kingdom-based independent review site for maternity products, for the brand’s V2 Hands-Free Breast Pump and its Seamless Floral Push Up Nursing Bra. The V2 pump was praised as “a very good value for the money” and “one of the best” on the market, while the nursing bra was lauded for its comfort and quality, described as “stays smooth without digging in” and “the best nursing bra” by a Bizziebaby reviewer. Momcozy’s portfolio of leading maternity and baby care items also received acclaim from the US-based Mom’s Choice Awards, a globally recognized program for family-friendly product and service reviews that evaluates thousands of items from over 60 countries. Momcozy’s trio of

MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 1029.2.2024 14:00:00 CET | Press release

MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10 A successful year including the announcements of positive data from two Phase 2 trials of sonelokimab in hidradenitis suppurativa (HS), at 12 and 24 weeks, and active psoriatic arthritis (PsA), at 12 weeks, supporting a potential best-in-class profile across two key indications Phase 3 preparation for sonelokimab in HS nearing completion, following positive feedback from both FDA and EMAYear-end cash, cash equivalents and short-term marketable debt securities of $511.0 million, expected to support a roadmap rich in potential catalysts whilst providing a cash runway to the end of 2026R&D Day to be held on Sunday March 10 – alongside the American Academy of Dermatology (AAD) annual meeting – expected to include 24 week data from the ARGO PsA study and PsA program next steps, final plans for the HS Phase 3 VELA program, analysis of the size of the HS market

Styrelsen i Cortus Energy beslutar om en företrädesemission av units om ca 107 MSEK och upptar kortsiktig lånefinansiering29.2.2024 13:55:00 CET | Pressemelding

EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARKEN DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, BELARUS, HONGKONG, JAPAN, KANADA, NYA ZEELAND, RYSSLAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING AV DETTA PRESSMEDDELANDE SKULLE VARA OLAGLIG ELLER KRÄVA YTTERLIGARE REGISTRERINGS- ELLER ANDRA ÅTGÄRDER. Styrelsen för Cortus Energy AB (”Cortus Energy” eller ”Bolaget”) har, under förutsättning av den extra bolagsstämmans godkännande bestående av aktier och teckningsoptioner av serie TO11 respektive TO12 med företrädesrätt för befintliga aktieägare om cirka 107 MSEK (”Företrädesemissionen”). Teckningsperioden löper under perioden från och med den 9 april 2024 till och med den 23 april 2024. Företrädesemissionen omfattas till cirka 70 procent av teckningsförbindelser och emissionsgarantier, bestående av både botten- och top-down garantiåtaganden. För att säkerställa finansieringsbehovet

HiddenA line styled icon from Orion Icon Library.Eye